Zentrum für Innere Medizin, Medizinische Klinik 1, Julius-Maximilians-Universität Würzburg, Oberdürrbacher Str. 6, Würzburg, 97080, Germany.
Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU München, Ziemssenstraße 5, München, 80336, Germany.
BMC Nephrol. 2024 Aug 8;25(1):256. doi: 10.1186/s12882-024-03691-y.
Symptoms of autonomic neuropathy (AN) are common in patients with diabetes and advanced renal disease. As yet different domains of autonomic neuropathy cannot be detected by a singular laboratory or invasive test. COMPASS 31, a new self-assessment test, has shown reliable results not only in cardiac autonomic neuropathy but also in different sub-domains when judging manifestation of AN by scores.
One hundred eighty-three patients with or without diabetes were enrolled, one hundred nineteen of them were treated with permanent dialysis therapy (HD), sixty-four patients served as controls (eGFR > 60 ml/min.) Using COMPASS 31 different symptoms of AN were assessed (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes) and transferred into AN-scores.
AN was more pronounced in dialysis patients compared with controls (AN-score 27,5 vs. 10,0; p < 0,01). These differences were present also in every sub-domain of AN (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes; p < 0,05 for all sub-domains). In diabetic patients there was a strong correlation between symptoms of AN and diabetes duration (correlation coefficient r = 0,45, p < 0,001). Current glycemic control (HbA1c), body mass index (BMI), sex, and height had no influence on AN when comparing dialysis patients and controls. C-reactive protein (CRP) showed a positive linear correlation with AN-scores (correlation coefficient r = 0,21; p < 0,05).
Symptoms of AN are more pronounced in dialysis patients not only in total but also in all different domains of neuropathic changes. Longlasting diabetic disease promotes development of AN, as duration of diabetes was positively correlated with AN. Future longitudinal studies might help to identify the high cardiovascular and mortality risk in dialysis patients by the easy-to-use COMPASS 31 without need of invasive and time-spending methods for diagnosing AN.
自主神经病变(AN)的症状在糖尿病和晚期肾病患者中很常见。目前,单一的实验室或侵入性检查无法检测到不同的自主神经病变领域。COMPASS 31 是一种新的自我评估测试,不仅在心脏自主神经病变方面,而且在通过评分判断 AN 表现的不同子领域方面,都显示出可靠的结果。
共纳入 183 例患者,其中 119 例为糖尿病患者,119 例接受永久性透析治疗(HD),64 例为对照组(eGFR>60ml/min)。使用 COMPASS 31 评估了不同的 AN 症状(直立不耐受、血管运动、分泌运动、胃肠道、膀胱、瞳孔运动变化),并转化为 AN 评分。
与对照组相比,透析患者的 AN 更为明显(AN 评分 27.5 对 10.0;p<0.01)。这些差异在 AN 的每个子领域(直立不耐受、血管运动、分泌运动、胃肠道、膀胱、瞳孔运动变化)中均存在(所有子领域的 p<0.05)。在糖尿病患者中,AN 症状与糖尿病病程之间存在很强的相关性(相关系数 r=0.45,p<0.001)。当前的血糖控制(HbA1c)、体重指数(BMI)、性别和身高在比较透析患者和对照组时对 AN 没有影响。C 反应蛋白(CRP)与 AN 评分呈正线性相关(相关系数 r=0.21;p<0.05)。
不仅在总 AN 评分中,而且在所有不同的神经病变变化领域,透析患者的 AN 症状更为明显。长期的糖尿病疾病促进了 AN 的发展,因为糖尿病的病程与 AN 呈正相关。未来的纵向研究可能有助于通过使用易于使用的 COMPASS 31 识别透析患者的高心血管和死亡率风险,而无需使用侵入性和耗时的方法来诊断 AN。